QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.101345v1 318/2/596    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by French, K. J. Articles by Smith, C. D. Search for Related Content PubMed PubMed Citation Articles by French, K. J. Articles by Smith, C. D.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Antitumor Activity of Sphingosine Kinase Inhibitors

Apogee Biotechnology Company, Hershey, Pennsylvania

Sphingosine kinase (SK) is an oncogenic sphingolipid-metabolizing enzyme that catalyzes the formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) at the expense of proapoptotic ceramide. Thus, SK is an attractive target for cancer therapy because blockage of S1P formation leads to inhibition of proliferation, as well as the induction of apoptosis in cancer cells. We have recently identified novel SK inhibitors with nanomolar to low micromolar potencies toward recombinant human SK. This study describes the continuing analysis of these inhibitors through in vitro and in vivo experiments. All three structurally diverse SK inhibitors tested showed antitumor activity in mice without exhibiting toxicity. Blood and tumor inhibitor concentrations exceeded in vitro potency levels. Cell signaling analyses in vitro revealed mixed inhibition of mitogen-activated protein kinase kinase and Akt phosphorylation by the SK inhibitors. Importantly, 4-[4-(4-chloro-phenyl)-thiazol-2-ylamino]-phenol (SKI-II) is orally bioavailable, detected in the blood for at least 8 h, and showed a significant inhibition of tumor growth in mice. These compounds are the first examples of nonlipid selective inhibitors of SK with in vivo antitumor activity and provide leads for further development of inhibitors of this important molecular target.

Address correspondence to: Dr. Kevin J. French, Apogee Biotechnology Company, P.O. Box 916, Hershey, PA 17033. E-mail: kjfrench{at}apogeebiotech.com

This article has been cited by other articles:

				G. Yan, S. Chen, B. You, and J. Sun Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids Cardiovasc Res, May 1, 2008; 78(2): 308 - 314. [Abstract] [Full Text] [PDF]

				V. Anelli, C. R. Gault, A. B. Cheng, and L. M. Obeid Sphingosine Kinase 1 Is Up-regulated during Hypoxia in U87MG Glioma Cells: ROLE OF HYPOXIA-INDUCIBLE FACTORS 1 AND 2 J. Biol. Chem., February 8, 2008; 283(6): 3365 - 3375. [Abstract] [Full Text] [PDF]

				J. Min, A. Mesika, M. Sivaguru, P. P. Van Veldhoven, H. Alexander, A. H. Futerman, and S. Alexander (Dihydro)ceramide Synthase 1 Regulated Sensitivity to Cisplatin Is Associated with the Activation of p38 Mitogen-Activated Protein Kinase and Is Abrogated by Sphingosine Kinase 1 Mol. Cancer Res., August 1, 2007; 5(8): 801 - 812. [Abstract] [Full Text] [PDF]

				S. Spiegel and S. Milstien Functions of the Multifaceted Family of Sphingosine Kinases and Some Close Relatives J. Biol. Chem., January 26, 2007; 282(4): 2125 - 2129. [Full Text] [PDF]